Saint Louis, MO – According to filings with the U.S. Securities and Exchange Commission, MediBeacon is raising $34,786,717.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Steven Hanley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MediBeacon

MediBeacon creates novel light-activated agents to enable medical innovations. A noninvasive real-time kidney function monitoring system is in human clinical trials. The MediBeacon system uses an optical skin sensor combined with a proprietary agent that glows in the presence of light. The goal is to provide clinicians continuous real-time monitoring of kidney function. MediBeacon has completed clinical studies in healthy and impaired subjects.

To learn more about MediBeacon, visit http://www.medibeacon.com/

Contact:
Steven Hanley, Chief Executive Officer
314-735-0975
hanley@medibeacon.com
https://www.linkedin.com/in/steve-hanley-8985ab11/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved